Science Explorer Back to mapMap
Discussion
Company · Rockville · United States

Supernus Pharmaceuticals (United States)

supernus.comROR OpenAlex
Research works
86
▲ 2% vs 2018-21
Citations
1.2k
14.1 per fractional work
Top-10% rate
7.9%
all institutions 10.0%
Open access
46%
world 40%
International
9%
world 18%
Supernus Pharmaceuticals (United States)

Not ranked overall: Supernus Pharmaceuticals (United States) is under the volume floor below which a citation excellence rate is noise. Not ranked is not the same as ranked last.

Which fields of science does Supernus Pharmaceuticals (United States) work in?

In 2022-now, 55% of research at Supernus Pharmaceuticals (United States) is in Health Sciences, 31% in Life Sciences. Its largest fields are Medicine (55%), Neuroscience (19%), Biochemistry, Genetics and Molecular Biology (12%). It does 2.0× the world's share of Health Sciences.

Health Sciences: 16 fractional works · 55.5% of its workMedicine: 16 fractional works · 55.4% of its workPsychiatry and Mental health: 6 fractional works · 21.5% of its workNeurology: 3 fractional works · 11.3% of its workPediatrics, Perinatology and Child Health: 2 fractional works · 6.1% of its workPharmacology: 2 fractional works · 5.4% of its workOncology: 0 fractional works · 1.5% of its workEpidemiology: 0 fractional works · 1.4% of its workEmergency Medicine: 0 fractional works · 1.1% of its workFamily Practice: 0 fractional works · 1.1% of its workGeriatrics and Gerontology: 0 fractional works · 1.1% of its workPulmonary and Respiratory Medicine: 0 fractional works · 1.1% of its workRadiology, Nuclear Medicine and Imaging: 0 fractional works · 1.1% of its workEndocrinology, Diabetes and Metabolism: 0 fractional works · 0.7% of its workRehabilitation: 0 fractional works · 0.6% of its workComplementary and alternative medicine: 0 fractional works · 0.4% of its workDermatology: 0 fractional works · 0.4% of its workPathology and Forensic Medicine: 0 fractional works · 0.3% of its workHealth Professions: 0 fractional works · 0.1% of its workLife Sciences: 9 fractional works · 31.3% of its workNeuroscience: 6 fractional works · 18.9% of its workCellular and Molecular Neuroscience: 3 fractional works · 9.8% of its workCognitive Neuroscience: 2 fractional works · 7.0% of its workBiological Psychiatry: 0 fractional works · 1.5% of its workBehavioral Neuroscience: 0 fractional works · 0.6% of its workBiochemistry, Genetics and Molecular Biology: 4 fractional works · 12.0% of its workMolecular Biology: 3 fractional works · 9.4% of its workCancer Research: 0 fractional works · 1.6% of its workPhysiology: 0 fractional works · 1.1% of its workPharmacology, Toxicology and Pharmaceutics: 0 fractional works · 0.4% of its workPharmacology: 0 fractional works · 0.4% of its workSocial Sciences: 2 fractional works · 7.2% of its workPsychology: 2 fractional works · 7.2% of its workExperimental and Cognitive Psychology: 1 fractional works · 3.7% of its workDevelopmental and Educational Psychology: 1 fractional works · 1.8% of its workClinical Psychology: 0 fractional works · 1.4% of its workApplied Psychology: 0 fractional works · 0.3% of its workPhysical Sciences: 2 fractional works · 6.0% of its workEnvironmental Science: 1 fractional works · 2.3% of its workHealth, Toxicology and Mutagenesis: 1 fractional works · 2.3% of its workComputer Science: 0 fractional works · 1.6% of its workComputational Theory and Mathematics: 0 fractional works · 1.1% of its workArtificial Intelligence: 0 fractional works · 0.2% of its workComputer Networks and Communications: 0 fractional works · 0.2% of its workChemistry: 0 fractional works · 1.5% of its workInorganic Chemistry: 0 fractional works · 1.1% of its workAnalytical Chemistry: 0 fractional works · 0.4% of its workMaterials Science: 0 fractional works · 0.4% of its workMaterials Chemistry: 0 fractional works · 0.4% of its workMathematics: 0 fractional works · 0.3% of its workStatistics and Probability: 0 fractional works · 0.3% of its workALL ITS WORKSupernusPharmaceuticals…29fractional works, 2022-now
Life Sciences31%Physical Sciences6%Health Sciences55%Social Sciences7%

Each ring splits the one inside it: the four domains of science, their fields, their subfields. Size is fractional works in 2022-now. Every slice is a page; the interactive view zooms down to single topics and colours each by how much more of it this institution does than the world.

Its 4 domains and 11 fields, with their numbers
    1. Medicine1655.4%
    2. Health Professions00.1%
    1. Neuroscience618.9%
    2. Biochemistry, Genetics and Molecular Biology412.0%
    3. Pharmacology, Toxicology and Pharmaceutics00.4%
    1. Psychology27.2%
    1. Environmental Science12.3%
    2. Computer Science01.6%
    3. Chemistry01.5%
    4. Materials Science00.4%
    5. Mathematics00.3%
All of science, and how each field's share has moved since 1950: the Science domain explorer

Field profile

Location quotient across every field it publishes in: outside the ring is more than an institution of this size would be expected to publish, inside it is less.

Biochemistry, Genetics and Molecular Biology: 2.26× its world share, 4 worksBiochemistry, Geneti…Neuroscience: 11.64× its world share, 6 worksNeurosciencePharmacology, Toxicology and Pharmaceutics: 1.07× its world share, 0 worksPharmacology, Toxico…Chemistry: 0.96× its world share, 0 worksChemistryComputer Science: 0.20× its world share, 0 worksComputer ScienceEnvironmental Science: 0.46× its world share, 1 worksEnvironmental ScienceMaterials Science: 0.11× its world share, 0 worksMaterials ScienceMathematics: 0.24× its world share, 0 worksMathematicsHealth Professions: 0.05× its world share, 0 worksHealth ProfessionsMedicine: 2.88× its world share, 16 worksMedicinePsychology: 2.36× its world share, 2 worksPsychology1×world share
more than its size predictsabout as predictedless

Rings at 0.5×, 1× and 2×. Widest outward: Neuroscience, 11.6×. Every wedge is a field page.

All 11 fields, with their numbers
  1. Neuroscience11.64×6 works
  2. Medicine2.88×16 works
  3. Psychology2.36×2 works
  4. Biochemistry, Genetics and Molecular Biology2.26×4 works
  5. Pharmacology, Toxicology and Pharmaceutics1.07×0 works
  6. Chemistry0.96×0 works
  7. Environmental Science0.46×1 works
  8. Mathematics0.24×0 works
  9. Computer Science0.20×0 works
  10. Materials Science0.11×0 works
  11. Health Professions0.05×0 works

Who are the top researchers at Supernus Pharmaceuticals (United States)?

Ranked on the quality score, Joseph T. Hull, Stefan Schwabe and Scott T. Brittain lead among researchers whose main affiliation is Supernus Pharmaceuticals (United States).

  1. 1 Joseph T. Hull United States · #419,859 worldwide 2.6k citations · 51 works
  2. 2 Stefan Schwabe United States · #825,864 worldwide 1.9k citations · 59 works
  3. 3 Scott T. Brittain United States · #880,882 worldwide 4.1k citations · 55 works
  4. 4 Nicholas Fry United States · #1,535,381 worldwide 334 citations · 16 works
  5. 5 Azmi F. Nasser United States · #1,586,673 worldwide 991 citations · 45 works
  6. 6 Alisa R. Kosheleff United States · #1,769,199 worldwide 532 citations · 21 works
  7. 7 Toyin Adewole United States · #1,871,725 worldwide 401 citations · 21 works
  8. 8 Zare Melyan United States · #2,067,503 worldwide 892 citations · 19 works
  9. 9 Gregory D. Busse United States · #2,090,350 worldwide 662 citations · 41 works
  10. 10 Tesfaye Liranso United States · #2,192,294 worldwide 487 citations · 37 works
All ranked researchers at Supernus Pharmaceuticals (United States)

What are the most cited papers from Supernus Pharmaceuticals (United States)?

The most cited paper from Supernus Pharmaceuticals (United States) is "Ion-exchange resins as drug delivery carriers" (Xiaodi Guo, Rong-Kun Chang, Munir A. Hussain, 2009), with 128 citations. Next come "New Insights into the Mechanism of Action of Viloxazine: Serotonin and Norepinephrine Modulating Properties" (93) and "Functional Impairments Associated With ADHD in Adulthood and the Impact of Pharmacological Treatment" (89).

Most cited papers
#PaperReleasedCitations
1 Ion-exchange resins as drug delivery carriers Xiaodi Guo, Rong-Kun Chang, Munir A. Hussain · Journal of Pharmaceutical Sciences 18 Feb 2009 128
2 New Insights into the Mechanism of Action of Viloxazine: Serotonin and Norepinephrine Modulating Properties Chung‐Ping Yu, Jennie García‐Olivares, Shawn A. Candler et al. · Journal of Experimental Pharmacology Open access Aug 2020 93
3 Functional Impairments Associated With ADHD in Adulthood and the Impact of Pharmacological Treatment Alisa R. Kosheleff, Oren Mason, Rakesh Jain et al. · Journal of Attention Disorders Open access 6 Mar 2023 89
4 A Phase III, Randomized, Placebo-controlled Trial to Assess the Efficacy and Safety of Once-daily SPN-812 (Viloxazine Extended-release) in the Treatment of Attention-deficit/Hyperactivity Disorder in School-age Children Azmi F. Nasser, Tesfaye Liranso, Toyin Adewole et al. · Clinical Therapeutics Open access 25 Jul 2020 85
5 A Phase II Double-Blind, Placebo-Controlled, Efficacy and Safety Study of SPN-812 (Extended-Release Viloxazine) in Children With ADHD Janet K. Johnson, Tesfaye Liranso, Keith E. Saylor et al. · Journal of Attention Disorders Open access 29 Mar 2019 62
All 63 most cited papers, with filters and sorting

Which keywords describe research at Supernus Pharmaceuticals (United States)?

By fractional works in 2022-now, weighted toward what it does more of than the world: Neurobiology, Treatment, Genetics, Prevalence, Brain Imaging, Meta-Analysis, ADHD and Attention-Deficit/Hyperactivity Disorder.

▲ more of its work than of the world's◆ about the world's share▼ less than the world's

Size is fractional works in 2022-now in the topics tagged with each word; colour is the word's share of this institution's work against its share of the world's. The 40 words are chosen for being large and distinctive. Each links to the topic it comes from most.

All 40 words, with their numbers
  1. Neurobiology7▲ 94×6 topics
  2. Treatment7▲ 19×5 topics
  3. Genetics7▲ 33×4 topics
  4. Brain Imaging6▲ 234×2 topics
  5. Prevalence6▲ 46×2 topics
  6. ADHD5▲ 495×1 topic
  7. Attention-Deficit/Hyperactivity Disorder5▲ 495×1 topic
  8. Meta-Analysis5▲ 31×2 topics
  9. Prefrontal Cortex4▲ 151×3 topics
  10. Serotonin3▲ 262×2 topics
  11. Neural Plasticity3▲ 56×3 topics
  12. Stress3▲ 27×2 topics
  13. Genetic Variation3▲ 44×2 topics
  14. Dopamine3▲ 379×1 topic
  15. Neurological Disorders3▲ 16×5 topics
  16. Reward Circuitry3▲ 379×1 topic
  17. Oxidative Stress2▲ 4.6×3 topics
  18. Parkinson's Disease2▲ 31×3 topics
  19. Toxicology2▲ 44×2 topics
  20. Epilepsy2▲ 57×2 topics
  21. Drug Development2▲ 67×2 topics
  22. Pain Management2▲ 26×3 topics
  23. Pharmacology2▲ 24×2 topics
  24. Depression2▲ 6.3×5 topics
  25. Treatment-Resistant Depression2▲ 83×2 topics
  26. Alzheimer's Disease2▲ 19×3 topics
  27. Diagnostic Criteria2▲ 22×3 topics
  28. Antiepileptic Drugs1▲ 65×2 topics
  29. Cognitive Function1▲ 26×4 topics
  30. Neurodevelopmental Disorders1▲ 30×2 topics
  31. Acetylcholinesterase1▲ 173×1 topic
  32. Botulinum Toxin1▲ 60×1 topic
  33. Cholinesterase Inhibitors1▲ 173×1 topic
  34. Crystal Structure1▲ 27×2 topics
  35. Deep Brain Stimulation1▲ 54×1 topic
  36. Emotion Regulation1▲ 12×2 topics
  37. Neurodegeneration1▲ 12×1 topic
  38. Neurotoxins1▲ 96×1 topic
  39. Subthalamic Nucleus1▲ 92×1 topic
  40. a-Synuclein1▲ 72×1 topic

Which research topics does Supernus Pharmaceuticals (United States) publish most on?

By volume in 2022-now: Attention Deficit Hyperactivity Disorder, Neurotransmitter Receptor Influence on Behavior, Parkinson's Disease Mechanisms and Treatments and Botulinum Toxin and Related Neurological Disorders.

Attention Deficit Hypera…5Attention Deficit Hyperactivity Disorder: 5 fractional worksNeurotransmitter Receptor Influence on Behavior: 3 fractional worksParkinson's Disease Mechanisms and Treatments: 1 fractional worksBotulinum Toxin and Related Neurological Disorders: 1 fractional worksCholinesterase and Neurodegenerative Diseases: 1 fractional worksNeurological disorders and treatments: 1 fractional worksEpilepsy research and treatment: 1 fractional worksNeural and Behavioral Psychology Studies: 1 fractional worksPharmacological Effects and Toxicity Studies: 1 fractional worksMental Health Research Topics: 1 fractional works
Psychiatry and Mental healthCellular and Molecular NeuroscienceNeurologyPharmacology3 others

Area is fractional works; colour is the subfield each topic belongs to.

  1. 1 Attention Deficit Hyperactivity Disorder Psychiatry and Mental health 5 works
  2. 2 Neurotransmitter Receptor Influence on Behavior Cellular and Molecular Neuroscience 3 works
  3. 3 Parkinson's Disease Mechanisms and Treatments Neurology 1 works
  4. 4 Botulinum Toxin and Related Neurological Disorders Neurology 1 works
  5. 5 Cholinesterase and Neurodegenerative Diseases Pharmacology 1 works
  6. 6 Neurological disorders and treatments Neurology 1 works
  7. 7 Epilepsy research and treatment Psychiatry and Mental health 1 works
  8. 8 Neural and Behavioral Psychology Studies Cognitive Neuroscience 1 works
  9. 9 Pharmacological Effects and Toxicity Studies Pediatrics, Perinatology and Child Health 1 works
  10. 10 Mental Health Research Topics Experimental and Cognitive Psychology 1 works

How open and international is its research?

Against the world's own shares: the tick on each track. Both are shares of its output, so they sit on one scale and can be read against each other as well as against the world.

openly available46.2%not open53.8%

World: 40% of research is openly available.

with international co-authors8.7%domestic only91.3%

World: 18% is written across borders.

How has Supernus Pharmaceuticals (United States)'s research output changed?

Output in 2022-2025 was 2% higher than in 2018-2021.

still counting200020052010201520202025
grewheldshrank

The same series as a ribbon: one cell per year, darker for more. The line above answers how much; this answers when.

Its share of all research

Growing output can still be a shrinking share: all of science grows. This is Supernus Pharmaceuticals (United States) as a percentage of every work published that year, 0.00016% in 2024.

still counting0.00010%0.00020%0.00030%Supernus Pharmaceuticals (United States)0.00014% in 2025200020102020

Fractional works of Supernus Pharmaceuticals (United States) over all fractional works that year. How the balance of science has shifted.

Other research institutions in Rockville

All research institutions in Rockville

Research measures only: rankings here say nothing about teaching, admissions or student experience. Comparable institutions and collaboration partners have tabs of their own, above.

Discussion

Ask a question or share a note about Supernus Pharmaceuticals (United States). Keep it to the research: no personal attacks, advertising or links. Any reader can report a post, which collapses it for everyone until it is opened.